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Abstract
Background: To assess the impact of polymorphisms in Glutathione S-transferase (GST) -P1, -
M1, and -T1 on self-reported chemotherapy-induced long-term toxicities in testicular cancer
survivors (TCSs).
Methods: A total of 238 TCSs, who had received cisplatin-based chemotherapy at median twelve
years earlier, had participated in a long-term follow-up survey which assessed the prevalence of
self-reported paresthesias in fingers/toes, Raynaud-like phenomena in fingers/toes, tinnitus, and
hearing impairment. From all TCSs lymphocyte-derived DNA was analyzed for the functional A→G
polymorphism at bp 304 in GSTP1, and deletions in GST-M1 and GST-T1. Evaluation of associations
between GST polymorphisms and self-reported toxicities included adjustment for prior treatment.
Results: All six evaluated toxicities were significantly associated with the cumulative dose of
cisplatin and/or bleomycin. Compared to TCSs with either GSTP1-AG or GSTP1-AA, the 37 TCSs
with the genotype GSTP1-GG, were significantly less bothered by paresthesias in fingers and toes (p
= 0.039, OR 0.46 [0.22–0.96] and p = 0.023, OR 0.42 [0.20–0.88], respectively), and tinnitus (p =
0.008, OR 0.33 [0.14–0.74]). Furthermore, absence of functional GSTM1 protected against hearing
impairment (p = 0.025, OR 1.81 [1.08–3.03]).
Conclusion: In TCSs long-term self-reported chemotherapy-induced toxicities are associated
with functional polymorphisms in GSTP1 and GSTM1. Hypothetically, absence of GST-M1 leaves
more glutathione as substrate for the co-expressed GST-P1. Also intracellular inactivation of pro-
apoptotic mediators represents a possible explanation of our findings. Genotyping of these GSTs
might be a welcomed step towards a more individualized treatment of patients with metastatic
testicular cancer.
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The progress of cisplatin-based chemotherapy has
changed the once dark prospects of disseminated testicu-
lar cancer (TC) into a model of a curable neoplasm [1,2].
This success story of oncological treatment however, is
shadowed by an increase in reports on long-term somatic
and psychosocial sequalae in testicular cancer survivors
(TCSs) [3,4]. Cisplatin (C) is the cornerstone of chemo-
therapeutic treatment of TC. It has usually been combined
with bleomycin (B), and vinblastine (V) as CVB regimen,
until Williams et al. 1987 demonstrated that substitution
of vinblastine by etoposide (E) as BEP regime resulted in
increased survival and less toxicities [5]. While peripheral
neurotoxicity can be induced by several of these drugs [6-
8], ototoxicity (tinnitus and/or impaired hearing) is
mainly ascribed to cisplatin [9,10]. Clinicians have
observed large inter-individual variations of treatment-
induced toxicities among patients after similar chemo-
therapy regimens. In animal models these variations have
been greater than explainable by variable pharmacoki-
netic properties [11]. These observations led to the
assumption of genetic differences in the elimination,
detoxification and/or toleration of cytotoxic agents
among patients.
Glutathione S-Transferases (GSTs) are enzymes which
have been linked to both the etiology of testicular cancer
[12], the cure rate of platinum-based chemotherapy [13],
and chemotherapy-induced toxicities [14]. GSTs are
expressed in the testicles and levels of GTP1 are increased
in case of acquired resistance to cisplatin [15,16]. GSTs
might moderate toxicities systemically but expression of
these enzymes at the affected site increases the credibility
of potential associations. GST-M1 and GST-P1 are both
expressed at the corti organ,[17] which is affected in case
of cisplatin-induced ototoxicity. Both enzymes are also
expressed in dorsal root ganglion cells,[18] which are
known to be damaged by cisplatin [19]. Further functions
of GSTs have been reviewed in detail elsewhere [20,21].
We considered germ-line polymorphisms within GST
genes as promising candidates for the exploration of the
large inter-individual variability of long-term treatment
toxicities. Recently, we reported on their importance for
cisplatin-induced audiometric assessed hearing impair-
ment [22]. In the present study we aimed to investigate
the relevance of functional genotype polymorphisms of
GST-M1,-P1 and-T1 for the prevalence of self-reported
long-term paresthesias, Raynaud-like phenomena, tinni-
tus, and hearing impairment in a large sample of cisplatin-
based chemotherapy treated TCSs.
Methods and patients
Patients
During the years 1998 to 2002, all Norwegian TCSs
treated between 1980 and 1994 and aged between 18 and
75 years were invited to participate in a long-term survey,
which consisted of a questionnaire and an out-patient
visit. Patients with evidence of active TC, extragonadal
germ cell malignancy, bilateral TC, a second non-germ
cell malignancy (except skin cancer), and those, in whom
the non-affected testicle had been removed previously due
to a benign condition, were excluded [23]. Post-orchiec-
tomy treatment was principally applied according to spec-
ified protocols as described previously [24]. Most patients
treated by chemotherapy received cisplatin (C) in combi-
nation with bleomycin (B), etoposide (E) or vinblastine
(V) as 3–4 courses of BEP or CVB. These regimens were
applied in conjunction with a rigorous hydration regime
in all patients. For the purpose of the present study, the
type of regimen, cumulative dosage per square meter body
surface [mg/m2] of the most commonly used cytotoxic
substances, exact number of cycles and dates of applica-
tion were retrieved from treatment charts. The present
study includes only TCSs, who have been treated with cis-
platin-based chemotherapy at the Norwegian Radium
Hospital (NRH) and for whom lymphocytes have been
available for DNA analyses.
Genotyping
Whole blood EDTA samples were collected from the TCSs,
lymphocyte-DNA extracted, and submitted to genetic
analyses of functional polymorphisms in the genes coding
for GSTT1, -M1, and -P1. 173 of the 238 TCSs included in
this study are the same as those previously reported by us
[22]. The known inherited homozygous deletions in
GSTT1 and GSTM1 are equivalent to non-functional
enzymes. A functional single nucleotide polymorphism
(SNP) in the GSTP1 gene at base pair 315 between Adeno-
sine (A) and Guanine (G) leads to the expression of either
isoleucine (Ile) or valine (Val) at codon 105 (Ile105,
Val105).
GST analysis was performed according to a previously
described multiplex PCR protocol [25]. Briefly, 50–100 ng
DNA and 30 pmol of each of the primers for GSTM1,
GSTT1, and GSTP1, and 10 pmol of the GSTmu2 anti-
sense primer, 1.4 mM MgCl2, PCR buffer II from Perkin
Elmer (MgCl2 free), and 0.75 Units Taq polymerase were
mixed. The fragment lengths of the PCR products were
480 base pairs (bp) for GSTT1, 294 for GSTP1, 275 for
GSTM1, and 175 bp for GSTM2 which served as a positive
PCR control. Subsequently, 20 μl of the PCR product
(unpurified) was digested with 8 Units of the restriction
enzyme Alw261 (MBI Fermentas, USA), and the frag-
ments were separated by agarose (4%) gel (NuSieve 3:1,
FCM Bioproducts, Rockland, ME, USA) electrophoresis.
The PCR products of GSTT1 and GSTM2 remain uncut,
whereas the GSTP1 fragment is cut into 234 bp and 60 bp
if codon 105 contains a G (guanine). GSTM1 contains a
nonpolymorphic Alw1261 restriction site and thereforePage 2 of 8
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ments in all samples positive for GSTM1 alleles,
(GSTM1+).
Questionnaire module (SCIN)
In this study we use a TC specific quality of life (QLQ)
module which was designed by Fossa et al. and used
together with the EORTC QLQ-C30 [26]. This module
was based on interviews with TCSs and reviews of the
available literature on long-term morbidity in TCSs and
was subsequently slightly modified and psychometrically
evaluated. It covers six symptoms (items), figure 1, and is
named: Scale for Chemotherapy-Induced Neurotoxicity
(SCIN) [27]. Summation of all six item scores, ranging
from 0 to 3, yields the SCIN-total-score which we consider
representing the overall chemotherapy-induced neurotox-
icity. In the present study we divided the SCIN-total-score
into three symptom-classes: none (0–5), moderate (6–9),
and severe (10–18).
The SCIN's psychometric properties have been validated
and were considered suitable for its application as screen-
ing instrument for chemotherapy-induced neurotoxicity
[27].
Statistical analyses
The above described item scores and the total-SCIN-score
represent ordered categorical variables. Associations
between genotypes and these scales were studied using
Chi-square tests and ordinal logistic regression analyses
(OLR), the latter approach allowing adjustment for age,
and chemotherapy parameters. The risk of an increment
within these scales attributed to specific parameters was
expressed as odds ratio (OR) with 95% confidence inter-
val (CI). Continuous variables were not normally distrib-
uted and are described with median and range. Each of
the response variables was analyzed once such that correc-
tion for multiple testing was not required. P-values < 0.05
were considered significant, P-values ≥ 0.05 and < 0.10
were reported as of marginal statistical significance. All
tests were two-tailed and the analyses were performed
using SPSS program version 12.0.2.
Ethics
The Committee for Medical Ethics of Health Region II of
Norway approved the protocol of the study. All patients
provided informed consent to participate in the study.
Results
A total of 238 TCS were eligible for the present study
(median age at diagnosis 29 years, range 15–64 years,
table 1). The median cumulative cisplatin dose was 397
mg/m2 (range: 81–1571 mg/m2). The majority (82%) of
patients received not more than one regimen of chemo-
therapy, which in 87% of such cases comprised BEP
(44%) or CVB (44%) and consisted usually of three to
four cycles (table 2). The SCIN was completed at median
12 years (range: 4–19 years) after initial diagnosis.
In univariate ORL analysis, cumulative doses of cisplatin
and bleomycin as well as age at survey were significantly
associated with the three-categorical SCIN-total-score
(table 2). In multivariate analysis only age at survey and
cumulative dose of cisplatin remained significant. Fur-
thermore, polymorphisms in GSTP1 had considerable
impact: TCSs with GSTP1-AA or GSTP1-AG had a more
than three-fold risk of a more severe symptom-class than
those with GSTP1-GG. Neither presence of functional
GSTT1 nor of functional GSTM1 was significantly associ-
ated with the SCIN-total-score.
The cumulative dose of cisplatin was significantly associ-
ated with paresthesias in the toes, Raynaud-like phenom-
ena in the toes and with both tinnitus and hearing
impairment (table 3). The risk of a more severe symptom-
class increased by roughly 1.3 for each step of 100 mg/m2
cumulative cisplatin, the dose corresponding to one cycle
of chemotherapy. Age at survey was significantly associ-
ated with the severity of each item except from tinnitus.
Paresthesias in fingers/toes as well as tinnitus and hearing
impairment were significantly associated with polymor-
phic alleles of GSTP1 and/or GSTM1. Presence of func-
tional GSTT1 was not associated with any of the item-
scores. Functional GSTM1 increased the risk of hearing
impairment by 1.8 (table 3). Furthermore, paresthesias in
Prevalence paresthesias in the fingers and toes, Raynaud-like phenomena in the toes, and tinnitus in TCSs depending on the GSTP1-GG geno ype, tatistical testing by χ2-trendsFigur  1
Prevalence paresthesias in the fingers and toes, Raynaud-like phenomena in the toes, and tinnitus in TCSs depending on the 
GSTP1-GG genotype, statistical testing by χ2-trends.Page 3 of 8
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in the toes showed a trend towards such an association.
Presence of both GSTP1-G alleles reduced the risk of
peripheral paresthesias in the fingers and in the toes, and
of tinnitus by at least the factor two. The association
between Raynaud-like phenomena in the toes was of a
similar magnitude, but only of marginal significance. No
symptom was significantly different between TCSs with
GSTP1-AG and GSTP1-AA (data not shown).
In order to illustrate these relations we depicted the scor-
ings of TCSs with either one or none GSTP1-G alleles (n =
201) opposed to those with both alleles (n = 37), figure 2.
Table 2: Association of SCIN-total-score with GST genotypes, age, and chemotherapy parameters by Ordinal Logistic Regression 
analysis
Categorical variables Symptoms class of SCIN-total-score Univariate Multiple†
GST genotype Number (%) No (0–5) Moderate 
(6–9)
Severe 
(10–18)
P OR (95% CI) P OR (95% CI)
P1 A/A 99 (41.6) 60 (60.6) 23 (23.2) 16 (16.2) 0.098 2.03 (0.88–4.67) 0.012 3.84 
(1.34–10.75)
A/G 102 (42.9) 53 (52.0) 29 (28.4) 20 (19.6) 0.014 2.83 (1.24–6.46) 0.003 4.95 
(1.70–14.45)
G/G 37 (15.5) 27 (73.0) 10 (27.0) 0 (0) Reference for GSTP1-AA and -AG
T1 + 201 (84.5) 118 (58.7) 51 (25.4) 32 (15.9) 0.770 1.11 (0.55–2.22) 0.714 1.17 (0.50–2.73)
- (ref.) 37 (15.5) 22 (59.5) 11 (29.7) 4 (10.8)
M1 + 134 (56.3) 79 (59.0) 35 (26.1) 20 (14.9) 0.947 0.98 (0.59–1.63) 0.166 1.56 (0.83–2.94)
- (ref.) 104 (43.7) 61 (58.7) 27 (26.0) 16 (15.4)
Continuous variables TCSs N (%) Median Minimum Maximum
Age at survey (OR for 10 
years)
238 (100%) 42.3 22.7 73.4 0.008 1.40 (1.09–1.80) 0.002 1.70 
(1.22–2.36)
OR* Cisplatin 238 (100%) 397 81 1571 <0.001 1.35 (1.11–1.49) 0.014 1.35 
(1.06–1.71)
Bleomycin 226 (95.0%) 142 0 212 0.040 1.65 (1.00–2.72) 0.078 1.43 (0.93–2.13)
Vinblastine 133 (55.9%) 9.9 0 51 0.535 1.49 (0.41–6.05) 0.319 0.23 (0.01–4.14)
Etoposide 92 (38.7%) 727 0 4934 0.092 1.00 (1.00–1.00) 0.918 1.00 (0.90–1.11)
*cumulative dose steps: bleomycin (100.000 IE/m2), cisplatin (100 mg/m2).
† Significant associations (bold), marginal significance (italics)
Table 1: Demographics of the 238 cisplatin-treated TCSs
Age at diagnosis, years Median (range) 29.3 (14.6 – 63.6)
Observation time, months Median (range) 11.8 (4.3 – 19.3)
Age at survey, years Median (range) 42.3 (22.7 – 73.4)
Histology, number (%) Seminoma: 44 (18.5%)
Non-seminoma: 194 (81.5%)
Stage according to Royal Marsden Hospital, number of patients (%) I: 72 (30.2%, incl. 2 IM)
II: 101 (42.4%)
III: 13 (5.5%)
IV: 52 (21.8%)
Number of cycles of chemotherapy 1–3: 52 (21.8%)
4: 141 (59.2%)
5–7: 34 (14.3%)
>8: 11 (4.6%)
First Regimen (n = 238)
Completed by 100% of TCSs
BEP: 104 (43.7%), CVB: 104 (43.7%), BOPVIP: 10 (4.2%), Others: 20 (8.4%)
Second Regimen (n = 44)
Completed by 18.5% of TCSs
BEP: 17 (39%), VIP: 12 (27%), EP: 5 (11%), Others: 10 (23%)
Third regimen (n = 8) VIP: 2, EP: 2, Others: 4
Fourth Regimen (n = 1) EP: 1
Number of TCSs exposed to the most common cytotoxic agents and 
cumulative doses among those [mg/m2], median (range)
Cisplatin (n = 238) : 397 (81 – 1571)
Bleomycin (n = 226) : 145 (29–212)
Vinblastine (n = 105) : 35 (10–51)
Etoposide (n = 146) : 1434 (41–4934)Page 4 of 8
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cantly protective effect of GSTP1-G homozygosity against
paresthesias in the fingers and toes (p = 0.040 and p =
0.025, respectively), Raynaud-like phenomena in the toes
(p = 0.032), and tinnitus (p = 0.003).
Discussion
After cisplatin-based chemotherapy, the risk of self-
reported peripheral paresthesias, Raynaud-like phenom-
ena in the toes, and tinnitus is halved in TCSs
homozygous for GSTP1-G compared to those with
GSTP1-AA/AG. Furthermore, presence of functional
GSTM1 nearly doubled the risk of hearing impairment.
GSTP1-GG proved highly protective against chemother-
apy-induced tinnitus (OR = 0.33). Cisplatin leads to loss
of outer hair cells in the cochlea [28], and thereby also to
hearing impairment [4], which was limited by absence of
GSTM1. In the subgroup of 173 TCSs in whom audiome-
try was performed such a beneficial effect of non-func-
tional GSTM1 was found for objectively measured
cisplatin-induced hearing impairment, which in addition
was strongly associated with the genotype GSTP1-GG
[22]. However, in the present study GSTP1-GG did not
protect against self-reported hearing impairment. One
possible explanation for this lack of association might be
a higher sensitivity of audiometric determination of hear-
ing thresholds at 4000 Hz – opposed to self-reported
hearing impairment. The cisplatin-induced hearing
impairment affects preferentially high frequencies which
are no prerequisite for language communication and
might thus, despite a measurable deterioration, not be
noticed by the affected individuals. Tinnitus appears to be
a more sensitive symptom for subjectively experienced cis-
platin-induced ototoxicity and its prevalence usually
increases with the individual's age [29]. In our TCSs how-
ever, the cisplatin-dose is of overriding importance caus-
ing GSTP1-GG to disclose its protective potential.
Paresthesias may represent a sequel to several drugs
applied in our TCSs: Oncovin, vinblastine, and etoposide
[30]. Cisplatin-induced paresthesias are experienced by
length-dependent symmetrical stocking distribution of
sensory symptoms [30]. The protective effect of GSTP1-
GG presence most likely mirrors an increased tolerance to
this drug.
Induction of acute myeloid leukemia is according to Rich-
iardi et al. 38 times more frequent in non-seminoma
patients who were treated by etoposide containing chem-
otherapy compared to the sex-, age-, period, and popula-
tion-specific incidence rates [31]. Intriguingly, Allan et al.
demonstrated a two-fold prevalence of chemotherapy-
induced leukemia among cancer survivors with GSTP1-
GG compared to those with GSTP1-AA or GSTP1-AG [32].
This risk increased to the odds ratio of four in patients
SCIN and its six items with the four possible scoresFigure 2
SCIN and its six items with the four possible scores.
 Items Not at all A little Quite a bit Very much 
fingers 
Are you suffering from pain, tingling, 
or numbness in your hands/fingers? 
0 1 2 3 
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toes 
Are you suffering from pain, tingling, 
or numbness in your feet/toes? 
0 1 2 3 
fingers 
Are you suffering from white/cold 
hands/fingers when it is cold? 
0 1 2 3 
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Are you suffering from white/cold 
feet/toes when it is cold? 
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tinnitus 
Are you suffering from ringing in 
your ears? 
0 1 2 3 
O
to
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ty
 
 
hearing 
impairment 
Are you suffering from impaired 
hearing? 
0 1 2 3 
 
Table 3: Association of SCIN items and relevant variables by ordinal Logistic Regression analysis
Age (OR for decadal 
steps)
Cisplatin (OR for steps of 
100 mg/m2)
GSTM1 (+ vs.- as 
Reference)
GSTT1 (+ vs.- as 
Reference)
GSTP1 (GG vs. AA/AG as 
Reference)
P OR 
(95%CI)*
P OR (95% 
CI)*
P OR (95% CI)* P OR P OR (95% CI)*
Paresthesias fingers 0.046 1.29 
(1.01–1.67)
0.178 1.11 
(0.95–1.29)
0.057 1.68 
(0.98–2.76)
0.926 1.03 0.039 0.46 
(0.22–0.96)
Paresthesias toes <0.001 1.82 
(1.40–2.37)
<0.001 1.34 
(1.14–1.57)
0.050 1.68 
(1.00–2.81)
0.704 0.88 0.023 0.42 
(0.20–0.88)
Raynaud's P. fingers 0.058 1.27 
(0.99–1.62)
0.021 1.27 
(1.03–1.39)
0.235 1.35 0.944 0.98 0.920 0.97
Raynaud's P. toes 0.022 1.34 
(1.04–1.72)
<0.001 1.33 
(1.14–1.56)
0.072 1.60 
(0.96–2.66)
0.355 0.73 0.052 0.49 
(0.24–1.01)
Tinnitus 0.153 1.20 0.001 1.32 
(1.12–1.55)
0.962 1.01 0.107 1.83 0.008 0.33 
(0.14–0.74)
Hearing Impairment <0.001 1.61 
(1.24–2.09)
<0.001 1.34 
(1.14–1.56)
0.025 1.81 
(1.08–3.03)
0.595 1.20 0.553 0.81
*(95% CI) only listed when the association was statistically significant (bold) or marginally significant (italics)Page 5 of 8
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cyclofosfamide, etoposide, or adriamycin.
Induction of leukemia and neurotoxicity by chemother-
apy is apparently curbed by strictly opposite GSTP1 poly-
morphisms. This seemingly contradiction might be due to
substrate specificity: Experiments with E.coli cloned with
human polymorphic GSTP1 indicate that topoisomerase
inhibitors are preferentially detoxified by GSTP1-A
whereas cisplatin is best inactivated by GSTP1-G [33]. The
examined SNP A→G causes substitution of isoleucine by
valine in GSTP1 at codon 105, a residue regulating the
affinity and detoxification efficacy for electrophilic sub-
strates [34]. E.coli with human GSTP1-G have a doubled
cytoprotection against cisplatin as compared to those with
GSTP1-A. Recently, GSTP1-G was demonstrated to protect
patients with gastric cancer against oxaliplatin-induced
neuropathy [35]. Taken together, studies in both bacteriae
and cancer patients indicate that GSTP1-GG protects its
carriers against platinum-induced toxicities.
The observed beneficial absence of GSTM1 could be
explained by a competition on glutathione (GSH) as sub-
strate of both GSTM1 and GSTP1. Both GST-M1 and GST-
P1 are co-expressed in the mammalian cochlea and in
dorsal root ganglion whose cells are linked to cisplatin-
induced paresthesias [17,18,36]. The latter may detoxify
cisplatin more effectively and might unfold more of its
protective potential when the competing GSTM1 is not
present. Supplementation of GSH demonstrated in a
small randomized placebo-controlled study protection
against oxaliplatin-induced neurotoxicity [37].
Alteration of intracellular apoptosis pathways might rep-
resent an alternative or additional explanation to varying
detoxification efficacies: GSTP1 monomers bind- and
thus inactivate the stress-inducible Jun N-terminal kinase
(JNK) [38]. Oxidative stress releases GSTP1 from JNK,
which in turn activates the expression of GSTP1 and other
genes involved in apoptosis and cytoprotection [39]. Inhi-
bition of JNK in cisplatin-treated guinea pigs increased
ototoxicity [40]. Hypothetically, protection against cispla-
tin-induced toxicities might be due to less effective JNK
inactivation by the GSTP1-G-derived enzyme
GSTP1105Val. Intriguingly, GSTM1 was found to be a
binding partner of the apoptosis signal-regulating kinase
1 (ASK-1). Binding of ASK-1 by GST-M1 inhibits its func-
tion and prevents thereby activation of JNK and p38 path-
ways [41]. Deletion of GST-M1, resulting in absence of
this functional enzyme might thereby increase the risk of
cisplatin-induced apoptosis. We admit that both pre-
sented functional explanations of our findings, i.e. inter-
action with cell signaling factors and competition on
glutathione as substrate for both GST-P1 and GST-M1,
remain theoretical ones. However, these hypotheses
appear readily refuted or supported by cell culture experi-
ments.
The role of antioxidants for neuro-protection in chemo-
therapy receiving patients is debated. Pace et al. demon-
strated Vitamin E to prevent cisplatin-induced
neurotoxicity to some extent,[42] however, a trial examin-
ing calcium- and magnesium salts in oxaliplatin receiving
cancer patients had to be stopped due to a lower response
rate compared to placebo[43]. It might be worthwhile to
examine neuro-protective effects of antioxidants with
respect to potentially important polymorphisms. Glutath-
ione's protective potential might correlate with GST poly-
morphisms. Hopefully, translation of these findings into
clinical practice includes prospective assessment of neuro-
protective agents and their modulation by functional pol-
ymorphisms.
Prediction of anticipated toxicities might help patients
and oncologists to choose individualized treatment.
Therefore, GST genotyping might become a helpful tool
for avoidance of chemotherapy-induced long-term toxici-
ties. The strongest limitation of our study might represent
the reliance on self-reported symptoms only. Objectively
measured findings, e.g. nerve conduction velocity and
Doppler-flow examination of the digital arteries after cold
exposure, would have facilitated the distinction between
paresthesias and Raynaud-like phenomena. Furthermore,
pre-treatment evaluations are not available, precluding
assessment of intra-individual treatment-related changes
over time. However, the high compliance-rate of this sur-
vey (81%) conducted more than ten years after treatment
is considered quite unique and the size and homogeneity
of the sample of TCSs might partly compensate for the
above mentioned limitations. The observed strong associ-
ation between SCIN and the cumulative cisplatin-dose
permits evaluation of protective genotypes.
In conclusion, presence of both GSTP1-G alleles and/or
absence of functional GSTM1 protect its carriers against
several chemotherapy-induced long-term toxicities.
Before clinical consequences can be discussed, these
results should be corroborated in an independent sample
of cancer patients. However, the concordance between
audiometrically evaluated cisplatin-induced hearing
impairment and the observations presented here builds a
strong case for the presence of relevant associations
between GST polymorphisms and long-term chemother-
apy-induced toxicities.
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